The International Generic and Biosimilar medicines Association (IGBA) announced today that it has established a CEO Advisory Committee composed of fourteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States.
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that GENEZIS has been accepted and welcomed as a new IGBA Associate Member.
- Vivian Frittelli takes over the position of IGBA Chair (January 2022)
- IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access (November 2021)
- Global Biosimilars Week: Message of Sudarshan Jain, Chair, IGBA (October 2021)
- Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid (October 2021)
